Literature DB >> 11097142

Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use.

G I Köhler1, S M Bode-Böger, R Busse, M Hoopmann, T Welte, R H Böger.   

Abstract

OBJECTIVES: Adverse drug reactions (ADRs) are a major cause of hospital admissions, thereby leading to significant medical and economical problems. Drug interactions contribute to a major part of ADRs, especially in elderly patients and in patients under polymedication. As a peculiarity of the German health care system the general practitioner is less involved in patient care during hospital stay than in other countries. Consequently, changes in medication at the transition point from out-patient to in-patient care and back may contribute to drug-related problems. PATIENTS: In the present study we investigated potential interactions in 169 consecutive patients with the diagnosis CHD (coronary heart disease) or COLD (chronic obstructive lung disease) who were admitted to the University Hospitals of Hannover and Magdeburg.
METHODS: For each patient, potential interactions between prescribed drugs at admission, at discharge, and 3 months after discharge were assessed by using drug interaction data bases.
RESULTS: We found that the number of drugs taken per patient as well as the number of interactions per patient are higher during hospitalization than before admission (pre-admission), and fall back after the hospital stay (post-discharge), but not to the pre-admission level. The number of potential interactions was significantly correlated in a polynomial manner to the number of drugs taken by each patient. The number of patients without a potential interaction was 44.4% pre-admission, 39.6% at discharge, and 39.1% post-discharge. Patients with potential interactions had a mean of 2.8, 2.7, and 2.4 interactions at each of the time points. Drug classes mainly involved with potential interactions were kaliuretic diuretics (recorded by 43.3% at discharge), ACE inhibitors (30.3%), anticoagulants and aggregation inhibitors (20.4%) and digitalis glycosides (14.7%). Regarding the frequency of the interaction categories, 68-70% of the potential interactions demand clinical attention, while 1-2% are life-threatening. 17-19% may result in therapeutic benefit; 10-12% are without clinical relevance.
CONCLUSIONS: The risk of drug interactions increases exponentially with the number of drugs given to a patient. Although we have no data on the fraction of interactions that became clinically manifest, our study indicates that prescribing fewer drugs can reduce the risk of suffering from sickness secondary to drug interactions. Taking this risk into account may help to improve the quality of drug treatment and to save costs.

Entities:  

Mesh:

Year:  2000        PMID: 11097142     DOI: 10.5414/cpp38504

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN: 0946-1965            Impact factor:   1.366


  75 in total

1.  The incidence of potential drug-drug interactions in elderly patients with arterial hypertension.

Authors:  Vesna Bacic-Vrca; Srecko Marusic; Viktorija Erdeljic; Slaven Falamic; Nives Gojo-Tomic; Dario Rahelic
Journal:  Pharm World Sci       Date:  2010-10-05

2.  Lack of awareness of community-acquired adverse drug reactions upon hospital admission : dimensions and consequences of a dilemma.

Authors:  Harald Dormann; Manfred Criegee-Rieck; Antje Neubert; Tobias Egger; Arnim Geise; Sabine Krebs; Thomas Schneider; Micha Levy; Eckhart Hahn; Kay Brune
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

3.  Characteristics and time course of severe glimepiride- versus glibenclamide-induced hypoglycaemia.

Authors:  A Holstein; A Plaschke; C Hammer; E-H Egberts
Journal:  Eur J Clin Pharmacol       Date:  2003-04-16       Impact factor: 2.953

4.  Tirofiban and eptifibatide treatment of patients presenting with acute coronary syndrome with non-ST segment elevation.

Authors:  Nuria Corominas; Joaquin Perez; Jose Ortiz; Elena Ferrer; Josep Ribas; Gines Sanz
Journal:  Pharm World Sci       Date:  2004-02

5.  Identifying adverse drug reactions associated with drug-drug interactions: data mining of a spontaneous reporting database in Italy.

Authors:  Roberto Leone; Lara Magro; Ugo Moretti; Paola Cutroneo; Martina Moschini; Domenico Motola; Marco Tuccori; Anita Conforti
Journal:  Drug Saf       Date:  2010-08-01       Impact factor: 5.606

6.  A purging procedure for pantoprazole and 4-lumen catheters to prevent IV drug incompatibilities.

Authors:  Thilo Bertsche; Carolin Veith; Alexander Stahl; Torsten Hoppe-Tichy; F Joachim Meyer; Hugo A Katus; Walter E Haefeli
Journal:  Pharm World Sci       Date:  2010-08-07

Review 7.  Orphan nuclear receptors as targets for drug development.

Authors:  Subhajit Mukherjee; Sridhar Mani
Journal:  Pharm Res       Date:  2010-04-06       Impact factor: 4.200

8.  Adverse drug reactions in an elderly hospitalised population: inappropriate prescription is a leading cause.

Authors:  Maria Cristina G Passarelli; Wilson Jacob-Filho; Albert Figueras
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

9.  Clinical relevance of drug-drug interactions : a structured assessment procedure.

Authors:  Eric N van Roon; Sander Flikweert; Marianne le Comte; Pim N J Langendijk; Wilma J M Kwee-Zuiderwijk; Paul Smits; Jacobus R B J Brouwers
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

10.  Interaction network among functional drug groups.

Authors:  Minho Lee; Keunwan Park; Dongsup Kim
Journal:  BMC Syst Biol       Date:  2013-10-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.